Behavioral and psychological impact of genome sequencing: a pilot randomized trial of primary care and cardiology patients

Kurt D. Christensen\textsuperscript{1,2,3,5}, Erica F. Schonman\textsuperscript{4}, Jill O. Robinson\textsuperscript{5}, J. Scott Roberts\textsuperscript{6}, Pamela M. Diamond\textsuperscript{7}, Kaitlyn B. Lee\textsuperscript{5}, Robert C. Green\textsuperscript{1,4,8,9,10} and Amy L. McGuire\textsuperscript{5}

Many expect genome sequencing (GS) to become routine in patient care and preventive medicine, but uncertainties remain about its ability to motivate participants to improve health behaviors and the psychological impact of disclosing results. In a pilot trial with exploratory analyses, we randomized 100 apparently healthy, primary-care participants and 100 cardiology participants to receive a review of their family histories of disease, either alone or in addition to GS analyses. GS results included polygenic risk information for eight cardiometabolic conditions. Overall, no differences were observed between the percentage of participants in the GS and control arms, who reported changes to health behaviors such as diet and exercise at 6 months post disclosure (48\% vs. 36\%, respectively, \(p = 0.104\)). In the GS arm, however, the odds of reporting a behavior change increased by 52\% per high-risk polygenic prediction (\(p = 0.032\)). Mean anxiety and depression scores for GS and control arms had confidence intervals within equivalence margins of \(\pm 1.5\). Mediation analyses suggested an indirect impact of GS on health behaviors by causing positive psychological responses (\(p = 0.001\)). Findings suggest that GS did not distress participants. Future research on GS in more diverse populations is needed to confirm that it does not raise risks for psychological harms and to confirm the ability of polygenic risk predictions to motivate preventive behaviors.

npj Genomic Medicine (2021) 6:72 ; https://doi.org/10.1038/s41525-021-00236-2

INTRODUCTION

Many experts expect genome sequencing (GS) to become a routine part of patient care\textsuperscript{12} and advocates envision a future where GS is used for screening purposes to identify predispositions for disease and facilitate targeted prevention\textsuperscript{1}. Others urge caution given the potential for patients and providers to be upset and confused by GS results\textsuperscript{4-6}. Empirical evidence to inform discussions about the benefits and harms of clinical use of GS is currently lacking, including for behavioral and psychological outcomes\textsuperscript{7}.

Extensive research on single-gene and panel genetic testing consistently show that identification of highly penetrant variants for modifiable conditions sometimes improves screening compliance, but sustained changes in lifestyle behaviors, such as physical activity and diet, are rare in at-risk and sick populations\textsuperscript{8-12}. Numerous studies have shown that negative psychological responses are also rare, even when findings indicate increased risks for conditions lacking proven preventive options\textsuperscript{10-17}. However, there are reasons to believe that individuals may respond differently to GS\textsuperscript{18}. GS can provide insight about any condition with established gene-disease associations, whereas single-gene and panel tests have traditionally been used to examine a predefined set of conditions. Results can also be unexpected and prior work has shown behavioral and psychological benefits to disclosing unanticipated secondary findings from single-gene testing\textsuperscript{14}. Moreover, GS can identify many types of risk factors, from monogenic disease risks for rare conditions to polygenic risk predictions for common diseases, to carrier status for autosomal recessive conditions. Consequently, behavioral and psychological outcomes have been a priority of research networks such as the Clinical Sequencing Exploratory Research (CSER) Consortium\textsuperscript{19}.

In this study, we analyzed data from the MedSeq Project, a pilot randomized trial of GS in cardiology and primary care. A prior descriptive summary of the primary-care cohort found new monogenic findings in 11 patients, two of whom had evidence of phenotypes predicted by those results. It also showed similar scores on scales of anxiety and depression at 6 months post disclosure and rates of self-reported health behavior changes that may have been higher following sequencing (41\% of patients receiving GS vs. 30\% of patients who did not\textsuperscript{20}). A meta-analysis that combined MedSeq data with data from other CSER sequencing sites showed decreases in anxiety and depression scores at 6 weeks post disclosure among patients who received GS\textsuperscript{21}.

Here we expand upon those analyses by reporting findings from the MedSeq Project, one of the first randomized studies of GS, and compared behavioral and psychological outcomes in patient-participants who received GS and family history (FH) reviews vs. patient-participants who only received FH reviews. A goal of this pilot project was to “generate novel hypotheses to inform the design of larger studies moving forward”\textsuperscript{22}. However, we also proposed the following exploratory hypotheses a priori: (1) patients who received GS would be more likely to report a change to a health behavior than patients who did not and (2) patients who received GS would show equivalent levels of general anxiety and depression as patients who did not. We summarize
findings from those analyses here as well as summarizing physician recommendations for behavior changes because of the important role physicians play in facilitating lifestyle modifications.23,24. We also summarize the impact of GS on psychological outcomes that included test-related distress, uncertainty, and positive impact, as well as affective responses to information of worry, happiness, concern, empowerment, disappointment, and relief. Finally, we examined whether certain psychological responses may have influenced whether or not GS led to health behavior changes.

RESULTS

Participant characteristics and genomic findings

Two hundred and four patient-participants were randomized in the study and 200 completed results disclosure sessions (Supplementary Fig. 1). Patient-participants were primarily non-Hispanic White, with most reporting a household income exceeding $100,000 and a college-level education or higher (Table 1). Physician-participants who disclosed results included seven cardiologists and nine primary-care physicians who reviewed FH information and GS findings, if applicable, with between 2 and 28 patient-participants each (mean: 12.5). As noted previously20,25, 24 of 49 (49%) cardiology patient-participants in the GS arm received findings related to their hypertrophic or dilated cardiomyopathy (HCM or DCM) diagnosis, including 1 patient whose prior panel testing was negative and 3 patient-participants who had a second variant of uncertain significance identified in addition to a variant of uncertain significance that had been identified previously. In addition, 8 cardiology patient-participants (16%) were identified with a secondary finding associated with a monogenic condition and 41 (84%) were identified with carrier status for at least 1 autosomal recessive condition. Among the 50 primary-care patient-participants randomized to GS, 13 (26%) were identified with a monogenic disease risk, including 2 patient-participants identified with variants associated with hemochromatosis who had been diagnosed with the condition previously. All 50 sequenced primary-care patient-participants (100%) were identified with carrier status for at least 1 autosomal recessive condition. As detailed in the “Methods” section, all patient-participants randomized to GS also received pharmacogenomic information about five common medications, as well as risk information about eight cardiometabolic traits.

Behavioral impact

Physician-participants were more likely to recommend lifestyle or medication changes to patient-participants in the GS arm compared to patient-participants in the control arm (23% vs. 12%, respectively; p = 0.036). In addition, cardiologists were more likely to recommend lifestyle or medication changes than primary-care physicians (22% vs. 9%, respectively; p = 0.002). However, all analyses of patient-reported behavioral outcomes were not statistically significant in analyses that compared randomization arms (all p > 0.06). At 6 months post disclosure, 48% of patient-participants in the GS arm and 36% of patient-participants in the control arm reported a change to at least one health behavior (p = 0.104, Table 2). Randomization status was also not statistically significant in cohort-specific analyses (Supplementary Table 1).

Within the GS arm, however, differences were observed by risk status (Table 3). The odds that physician-participants recommended a behavior change during disclosure sessions increased by 68% for each high-risk polygenic risk finding (p = 0.049). Similarly, the odds that patient-participants reported a health behavior change increased by 49% at 6 weeks and 52% at 6 months for each high-risk polygenic risk finding (p = 0.049 and 0.032, respectively).

Psychological impact

Twenty-eight percent of patient-participants in the GS arm and 29% of patient-participants in the control arm reported Hospital Anxiety and Depression Scale (HADS) scores indicating at least moderate anxiety or depression at one or more post-disclosure

Table 1. Participant characteristics.

| Characteristic | Control (n=101) | Primary care (n=100) |
|---------------|----------------|---------------------|
| Mean age (SD) | 55.9 (14.2)    | 54.8 (7.3)          |
| Age range     | 18.7–84.6      | 41.2–67.9           |
| Gender        |                |                     |
| Female        | 43 (42%)       | 58 (58%)            |
| Male          | 57 (57%)       | 42 (42%)            |
| Race          |                |                     |
| Non-Hispanic White | 88 (88%) | 87 (87%) |
| Other         | 12 (12%)       | 13 (13%)            |
| Annual Household Income |          |                     |
| <$100,000     | 43 (43%)       | 25 (26%)            |
| ≥$100,000     | 53 (53%)       | 71 (74%)            |
| No response   | 4 (4%)         | 4 (4%)              |
| Education     |                |                     |
| Did not graduate from college | 22 (22%) | 14 (14%) |
| College graduate or higher | 78 (78%) | 86 (86%) |
| Has health insurance | 100 (100%) | 98 (98%) |
| Diagnosis (cardiology cohort) |         |                     |
| Hypertrophic cardiomyopathy | 79 (79%) |         |
| Dilated cardiomyopathy | 21 (21%) |         |

Table 2. Percentage of providers reporting health behavior change recommendations or patients reporting health behavior changes.

| Time point/behavior | Control (n=101) | GS (n=99) | OR (95% CI) | p   |
|---------------------|-----------------|-----------|-------------|-----|
| Provider recommendations |                 |           |             |     |
| Any change          | 12%             | 23%       | 2.3 (1.1–5.2) | 0.036 |
| Health behavior     | 12%             | 19%       | 1.8 (0.8–4.0) | 0.157 |
| Medication          | 2%              | 7%        | 3.9 (0.9–27.2) | 0.100 |
| Changes at 6 weeks  |                 |           |             |     |
| Any change          | 35%             | 42%       | 1.3 (0.7–2.4) | 0.356 |
| Exercise            | 22%             | 26%       | 1.2 (0.6–2.3) | 0.612 |
| Diet                | 23%             | 29%       | 1.4 (0.7–2.7) | 0.323 |
| Supplements         | 12%             | 7%        | 0.5 (0.2–1.5) | 0.226 |
| Medications         | 9%              | 11%       | 1.3 (0.5–3.3) | 0.640 |
| Other               | 7%              | 3%        | 0.4 (0.1–1.7) | 0.217 |
| Changes at 6 months |                 |           |             |     |
| Any change          | 36%             | 48%       | 1.6 (0.9–2.9) | 0.104 |
| Exercise            | 23%             | 35%       | 1.8 (1.0–3.5) | 0.064 |
| Diet                | 25%             | 35%       | 1.6 (0.9–3.1) | 0.126 |
| Supplements         | 10%             | 7%        | 0.6 (0.2–1.8) | 0.356 |
| Medications         | 15%             | 14%       | 0.9 (0.4–2.0) | 0.783 |
| Other               | 7%              | 3%        | 0.5 (0.1–1.9) | 0.270 |

Percentages, and means and 95% confidence intervals of odds ratios were estimated using logistic regression or generalized estimating equations using logit linking functions and binomial distributions.
time point, with no differences observed by randomization status ($p > 0.99$). Analyses of general anxiety and depression (Table 4) showed mean scores well below cutoffs for mood disorders, regardless of randomization status, at all time points and data supported equivalence between randomization arms at all time points. Moreover, at 6 weeks post disclosure, mean scores were lower in the GS arm compared to the control arm on measures of depression (difference: $-0.7$, $p = 0.015$) and positive impact (difference: $-2.1$, $p = 0.001$), suggesting lower depression and more positive feelings among those receiving GS. Cohort-specific analyses (Supplementary Table 2) were generally consistent with these findings. In the GS arm, differences in positive impact observed at 6 weeks persisted at 6 months among cardiology patient-participants (difference: $-1.9$, $p = 0.046$), whereas lower depression scores among primary-care patient-participants were observed at post disclosure (difference: $-0.8$, $p = 0.046$) and at 6 months (difference: $-0.8$, $p = 0.037$).

Analyses of affective responses (Supplementary Table 3) showed that patient-participants in the GS arm were more likely than patient-participants in the control arm at all post-disclosure time points to report feeling happy, empowered, and relieved by their test results ($all p < 0.001$). They were also less likely to feel disappointed at all time points ($all p < 0.004$), although they were more likely to feel confused ($all p \leq 0.013$). Immediately post disclosure, patient-participants in the GS arm were more likely than patient-participants in the control arm to report feeling worried about their test results ($39\%$ vs. $22\%$, respectively, $p = 0.011$), although differences did not persist at 6 weeks and beyond. Analyses of affective responses within the primary-care and cardiology cohorts (Supplementary Table 2) were mostly consistent with analyses across cohorts.

Analyses restricted to the GS arm also showed differences on psychological measures according to risk status (Supplementary Table 4). Interestingly, patient-participants who received results about an unexpected monogenic disease risk scored lower than patient-participants who were not identified with an unexpected monogenic disease risk on measures of depression immediately post disclosure (2.3 vs. 3.5, respectively, $p = 0.008$) and anxiety at 6 weeks (3.2 vs. 4.1, respectively, $p = 0.009$). Similarly, patient-participants’ uncertainty scores were lower when patient-participants had more high-risk polygenic risk predictions ($-0.5$ points per finding, $p = 0.029$).

### Mediation analyses

Scores on five psychological measures were associated with both randomization status and the likelihood of reporting a health behavior change at $p < 0.05$ in bivariate analyses: general depression, positive impact, and happy, empowered, and relieved feelings. Mediation analyses summarized in Table 5 suggested that GS prompted health behavior change by making patient-participants feel a greater positive impact from testing or more happy, empowered, or relieved about the information they received (all $p < 0.001$ for indirect associations between GS and health behavior changes). No indirect effects were observed for physician recommendations for lifestyle change ($p = 0.195$). Mediation analyses only examined the associations between randomization status, psychological outcomes or provider recommendations, and health behavior changes, and omitted variables about high-risk GS results.

### DISCUSSION

The MedSeq Project is a pilot randomized trial that provides preliminary evidence about the behavioral and psychological impact of GS, to inform future research. Results supported the hypothesis that GS would not increase risks for anxiety or depression and showed that patient-participants who received GS felt more positive about the information in the short-term. Results from exploratory analyses also provided some evidence that polygenic risk predictions for cardiometabolic traits may be able to motivate health behavior changes. Finally, exploratory analyses suggested a greater likelihood of impact of GS on health behaviors if patient-participants had positive psychological responses from receiving their GS results.

Overall, findings present early evidence that is somewhat encouraging about the potential behavioral and psychological impact of integrating GS into patient care. It is notable that physician- and patient-participants were both sensitive to the number of risks identified and to the ability to reduce cardiac risks with lifestyle modifications. Our findings align with two recently published studies showing benefits from disclosing genetic risk information about cardiovascular disease$^{14,26}$. Common to both these studies—and ours—are patient populations that were not recruited based on a preexisting

### Table 3. Associations between high-risk results, provider recommendations, and patient-reported health behavior changes.

| Time point/ behavior | Monogenic disease risk (ref: none) OR (95% CI) | Cardiometabolic risk prediction (per condition in 80th percentile risk) OR (95% CI) | $p$ | $p$ |
|----------------------|----------------------------------------------|--------------------------------------------------------------------------------|-----|-----|
| Recommendations       |                                              |                                                                                |     |     |
| Any change           | 0.59 (0.15–1.84)                             | 0.391 (1.68 (1.07–2.72)                                                    | 0.027 |     |
| Health behavior      | 0.79 (0.21–2.50)                             | 0.702 (1.41 (0.88–2.32)                                                    | 0.161 |     |
| Medication           | 1.51 (0.19–8.41)                             | 0.652 (1.99 (0.94–4.97)                                                    | 0.097 |     |
| Changes at 6 weeks   |                                              |                                                                                |     |     |
| Any change           | 1.72 (0.62–4.79)                             | 0.292 (1.49 (1.00–2.23)                                                    | 0.049 |     |
| Exercise             | 1.94 (0.66–5.74)                             | 0.228 (1.54 (0.99–2.41)                                                    | 0.057 |     |
| Diet                 | 1.60 (0.55–4.67)                             | 0.387 (1.27 (0.83–1.96)                                                    | 0.266 |     |
| Medications          | 1.73 (0.30–9.92)                             | 0.534 (1.25 (0.54–2.86)                                                    | 0.602 |     |
| Supplements          |                                              |                                                                                |     |     |
| Medications          | 0.37 (0.04–3.21)                             | 0.366 (1.28 (0.64–2.56)                                                    | 0.474 |     |
| Other                | NA*                                          | 0.568 (0.48 (0.08–2.94)                                                    | 0.424 |     |
| Changes at 6 months  |                                              |                                                                                |     |     |
| Any change           | 2.11 (0.74–6.03)                             | 0.160 (1.52 (1.04–2.24)                                                    | 0.032 |     |
| Exercise             | 2.39 (0.85–6.72)                             | 0.098 (1.59 (1.05–2.40)                                                    | 0.029 |     |
| Diet                 | 1.88 (0.67–5.27)                             | 0.227 (1.34 (0.91–1.98)                                                    | 0.134 |     |
| Medications          | 0.79 (0.08–7.39)                             | 0.832 (1.23 (0.59–2.57)                                                    | 0.571 |     |
| Other                | 2.03 (0.16–25.50)                            | 0.578 (1.06 (0.32–3.53)                                                    | 0.918 |     |

High-risk results were defined in two ways: (1) identification of an unexpected monogenic disease risk (analyses exclude two patients who were previously diagnosed with hemochromatosis, who received monogenic disease risk findings on their GS report) and (2) number of polygenic predictions about cardiometabolic traits (range: 0–8) where patients were identified to be in the 80th percentile for genetic risk, per polygenic risk predictions. Means and 95% confidence intervals of odds ratios were estimated using logistic regression or generalized estimating equations using logit linking functions and binomial distributions.

*An odds ratio could not be estimated, because no participant with an unexpected monogenic disease risk reported a change to this category at 6 weeks post disclosure. The $p$-value was estimated using a Fisher’s exact test on available data.
interest in reducing cardiovascular disease risks. It is possible that the behavioral impact of genetic risk disclosure is greatest for individuals when the information is unexpected\(^6\). Another explanation is that the MedSeq Project attracted patients who were motivated to enact health behavior changes, as was observed in related work\(^9\). A third possibility is that patients with low-risk genomic findings were falsely reassured by their findings, and that they were less likely to make health behavior changes than comparable patient-participants in the control arm. We did not test this explanation in this manuscript, but it may explain the null behavioral findings in comparisons of randomization arms despite a greater likelihood of behavior changes with increased risks for cardiometabolic traits.

Findings from our study may also help allay fears about the distress that GS may cause, particularly regarding secondary increased risks for cardiometabolic traits.

### Summary of mediation analyses

| Mediator | Indirect effect | p     | Direct effect | p     |
|----------|----------------|-------|---------------|-------|
| HADS: Depression | 3% (0% to 6%) | 0.065 | 9% (−4% to 23%) | 0.186 |
| MICRA: Positive | 7% (3% to 12%) | <0.001 | 4% (−9% to 18%) | 0.559 |
| Happy | 8% (1% to 16%) | <0.001 | 4% (−12% to 19%) | 0.640 |
| Empowered | 10% (4% to 17%) | <0.001 | 1% (−13% to 16%) | 0.782 |
| Relieved | 10% (3% to 17%) | <0.001 | 2% (−13% to 17%) | 0.753 |

Analyses examined whether the impact of randomization to GS on health behavior changes reported at 6 months were mediated by psychological responses at 6 weeks. Indirect effects are the differences between the GS and control arms in the likelihood of reporting a health change after controlling for the potential mediators. Direct effects are the differences between the GS and control arm in the likelihood of reporting a health behavior change after controlling for the potential mediators.

Table 5. Summary of mediation analyses.

| Time point/outcome | Control (n = 101) | GS (n = 99) | Difference (95% CI) | p     |
|--------------------|------------------|-------------|---------------------|-------|
| Baseline\(^a\)     |                  |             |                     |       |
| HADS: Anxiety      | 5.1 (0.2)        | 5.1 (0.2)   | 0.1 (−0.6 to 0.9)   | 0.790 |
| HADS: Depression   | 2.3 (0.2)        | 2.3 (0.2)   | −0.6 (−1.0 to 0.0)  | 0.052 |
| Post-disclosure    |                  |             |                     |       |
| HADS: Anxiety      | 4.8 (0.3)        | 4.9 (0.2)   | −0.5 (−1.2 to 0.2)  | 0.166 |
| HADS: Depression   | 2.7 (0.2)        | 2.1 (0.2)   | −0.7 (−1.2 to −0.2) | 0.015 |
| MICRA: Distress    | 0.2 (0.1)        | 0.4 (0.1)   | 0.2 (−0.1 to 0.6)   | 0.212 |
| MICRA: Uncertainty | 1.2 (0.2)        | 1.6 (0.3)   | 0.4 (−0.3 to 1.2)   | 0.312 |
| MICRA: Positive    | 10.0 (0.4)       | 7.9 (0.4)   | −2.1 (−3.3 to −0.9) | 0.001 |
| 6 Weeks            |                  |             |                     |       |
| HADS: Anxiety      | 4.1 (0.2)        | 3.6 (0.3)   | −0.3 (−0.8 to 0.2)  | 0.244 |
| HADS: Depression   | 2.4 (0.2)        | 1.7 (0.2)   | −0.7 (−1.2 to −0.2) | 0.015 |
| MICRA: Distress    | 0.2 (0.1)        | 0.4 (0.1)   | 0.2 (−0.1 to 0.6)   | 0.212 |
| MICRA: Uncertainty | 1.2 (0.2)        | 1.6 (0.3)   | 0.4 (−0.3 to 1.2)   | 0.312 |
| MICRA: Positive    | 10.0 (0.4)       | 7.9 (0.4)   | −2.1 (−3.3 to −0.9) | 0.001 |
| 6 Months           |                  |             |                     |       |
| HADS: Anxiety      | 4.7 (0.3)        | 5.0 (0.2)   | 0.3 (−0.5 to 1.0)   | 0.500 |
| HADS: Depression   | 2.6 (0.2)        | 2.2 (0.2)   | −0.3 (−0.8 to 0.2)  | 0.244 |
| MICRA: Distress    | 0.4 (0.1)        | 0.5 (0.2)   | 0.1 (−0.3 to 0.6)   | 0.613 |
| MICRA: Uncertainty | 1.4 (0.3)        | 1.7 (0.3)   | 0.3 (−0.4 to 1.3)   | 0.452 |
| MICRA: Positive    | 10.9 (0.4)       | 10.1 (0.5)  | −0.8 (−2.1 to 0.6)  | 0.260 |

Means (SEs) of scores were estimated using generalized estimating equations using linking functions and distributions that varied by outcome.

*Baseline scores represent the means and SEs across arms because scores at other time points are adjusted for differences at baseline. Unadjusted means for the control and GS arms at baseline were 4.8 vs. 5.4, respectively, for anxiety (p = 0.178) and 2.3 vs. 2.4, respectively, for depression (p = 0.661).
polygenic risk predictions for cardiometabolic traits. The large amount and different types of information in our GS reports likely explains why approximately one in six MedSeq patient-participants also reported some confusion at 6 months follow-up and prior reported results showed that patient-participants who received GS reported poorer understandings of the information they received

It is possible that positive responses to GS may have been even stronger if findings were easier to understand or strategies were more explicitly discussed. On the other hand, uncertainty scores at 6 months were lower among patients with more polygenic risks for cardiometabolic traits. It is possible that uncertainty scores were lower, because physicians were more engaged with these patients, as suggested in prior reported MedSeq analyses.

Another important finding from our analyses was the role of positive psychological responses in predicting behavioral outcomes. Prior work has speculated about how psychological responses to genomic test results might lead to behavior change, but our study is one of the first to examine this relationship empirically. Interestingly, although many health behavior theories posit that individuals will make lifestyle adjustments as an adaptive response to negative emotions such as fear and anxiety, our data suggest that GS may have motivated health behavior changes among those with positive emotional responses to receiving their GS results. Positive emotional states may facilitate health behavior change by enhancing resolve and making individuals more resilient to barriers such as tiredness and unaccommodating built environments. These findings add weight to calls for better understanding of psychological responses to genomic information, including positive emotions. Notably, positive emotional outcomes are often omitted from research on genomic testing.

Limitations to this study include limited sample size and statistical power in exploratory analyses, which did not account for multiple hypothesis testing or potential confounding with provider. Analyses did not allow us to determine what type of FH or genomic information motivated self-reported behavior changes. Provider- and patient-participants were early adopters and thus were self-selected, highly educated and affluent, and motivated to receive information from GS. Physician understandings of FH or genomic results were not assessed, although analyses showed that primary-care physicians responded to unexpected monogenic disease risks appropriately, in general. Patients were primarily non-Hispanic White and were recruited by a trusted physician into a study run by a well-respected research institution. All patients in the cardiology cohort received genetic testing for their condition previously, including some who received exome or GS. Findings may not generalize to other study populations or contexts, including those where improving lifestyles is the primary patient outcome. In those contexts, more appropriate comparators would be interventions with more proven efficacy.

Data analytic issues were also limitations. We did not track resources that physician-participants used to respond to the reports they received, including clinical decision support sheets for FH. Some of the survey measures were not validated and were dichotomized in analyses that grouped response options such as “slightly” and “extremely” together. Health behavior measures were simple yes/no questions about broad domains, have not been validated, did not provide insight about whether changes were clinically meaningful, and may have been subject to self-report bias. Mediation analyses were limited to testing whether 6-week psychological outcomes predicted 6-month behavioral outcomes, as posited prior to the trial. The reverse relationship and reciprocal relationship also merit examination. The definitions of “high-risk results” were also created for this study, with an emphasis on unexpected genomic information. Given that we did not define high-risk FH, a comparable definition of high-risk results were not incorporated for the control arm. Alternative approaches to characterizing “high-risk results” could include allowing patient-participants to decide for themselves whether they received high-risk results or developing consensus approaches investigators from other studies of genomic sequencing. Analyses of polygenic risk predictions may also benefit from creating a measure of low-risk results, given the potential for false reassurance. Such analyses could implement a measure with an emphasis on the number of conditions where patients were at the lowest percentiles of genetic risk for cardiometabolic traits.

Nevertheless, findings from our pilot trial present critical early evidence about the psychological and health behavior impact of integrating GS into broad clinical care, to inform future research with more diverse participants. As the accessibility of GS expands, capitalizing on GS’s ability to identify unknown health risks may have health promotion benefits.

METHODS

Study design and participants

The MedSeq Project was a pilot randomized trial to understand the impact of integrating GS into two clinical contexts: cardiology care of patients with diagnoses of genetic conditions and primary care of healthy patients. These contexts were targeted to provide insight about two archetypal scenarios, about how GS could be integrated into clinical care, as follows: (i) disease-specific genomic medicine, where testing focuses on identifying variants in relevant disease-associated genes; and (ii) general genomic medicine, where testing informs routine preventive medicine. Details of the study design, genomic analyses, recruitment, and enrollment have been published elsewhere. Briefly, 9 cardiologists and 11 primary-care physicians were enrolled into the study and enlisted their patients into the study protocol. Study staff recruited patients using letters and via telephone. Eligible primary-care patients were generally healthy adults aged 40–65 years when approached for recruitment. Eligible cardiology patients were adults of any age with diagnoses of HCM/DCM, who had previously received prior or concurrent panel-based genetic testing, to try to find a genetic explanation for their condition. Exclusion criteria included ongoing pregnancies and lack of English fluency. All patients with diabetes and primary-care patients with cardiovascular disease were also excluded because GS reports included polygenic risk predictions for associated phenotypes. Patients completed an FH tool, provided blood for potential sequencing, and completed a baseline survey.

Patients who completed the baseline survey were randomized to review their FH alone (control arm) or in conjunction with a GS report (GS arm) during a 2-hour disclosure meeting with their physician. Participants’ randomization statuses were computer-registered and drawn in sequence from sealed envelopes after participants completed the baseline questionnaire. Cardiologists in both arms also reviewed prior HCM/DCM genetic testing results. FH and GS reports, if applicable, were sent to patients’ physician-participants 1 week in advance of results disclosure sessions.

Methods for GS analysis, interpretation, results presentation, and sample GS reports were published previously. FH reports were generated using a customized version of the U.S. Surgeon General’s “My Family Health Portrait” web tool and included pedigrees and written summaries. FH reports did not highlight potentially concerning results, but were accompanied by six clinical decision support modules to help physicians interpret and manage FH information about breast and colon cancer, coronary artery disease, type 2 diabetes, glaucoma, and osteoporosis. GS reports communicated monogenic disease risks, regardless of whether the associated conditions had proven prevention strategies. GS reports also included carrier status for autosomal recessive conditions, pharmacogenomic information about five drugs, predicted lipid profiles, blood antigen predictions, and polygenic risk information about eight cardiometabolic traits as follows: abdominal aortic aneurysm, atrial fibrillation, coronary heart disease, type 2 diabetes, hypertension, obesity, platelet aggregation, and QT prolongation. At the time of the study, the laboratory examined between 3 and 70 loci for each trait to generate polygenic risk estimates. FH and GS reports did not include numeric estimates of disease incidence, although polygenic risk predictions included estimates of relative risks and percentiles of genetic risk.

Physician-participants were responsible for communicating FH and GS reports, as applicable, to their patients at their own discretion. Reports were typically sent by MedSeq Project staff to physician-participants a week in advance of a disclosure visit. At any time, providers could contact a
Genome Resource Center staffed by study-affiliated medical geneticists and genetic counselors with questions. The aforementioned decision support modules were also provided to help with managing FH reports. No other clinical decision support was provided. FH and GS reports were integrated into patients’ medical records after results were disclosed to patient-participants.

Patient-participants were surveyed immediately after disclosure and again 6 weeks and 6 months post disclosure. Physician-participants completed brief surveys immediately after disclosure where they reported any recommendations they made in response to FH or GS reports regarding medications and health behaviors. Patients provided written informed consent at their baseline visit, whereas physicians provided written informed consent during an in-person educational session prior to returning any results to patients. Participants were followed from 2012 to 2016. The Mass General Brigham (formerly Partners HealthCare) Human Research Committee and the Baylor College of Medicine Institutional Review Board both approved this study. Written informed consent was obtained in-person from participants. Our study conforms to the Declaration of Helsinki. The study was registered at ClinicalTrials.gov with identifier NCT01736566 on 29 November 2012.

Measures

Patients reported demographic information on the baseline survey. Exploratory behavioral and psychological outcomes of interest are described below. Psychological measures in the MedSeq Project were selected to facilitate analyses with other studies that were also part of the CSER Consortium. Behavioral measures were broad in scope, because specific changes to lifestyle were not a focus of our study, nor was GS tailored to address specific conditions that may benefit from targeted prevention. Given the pilot nature of this study, most measures were implemented to provide insight that could inform future trials rather than to make decisive conclusions about behavioral and psychological outcomes.

Health behaviors

Physician recommendations. Immediately post disclosure, physician-participants completed checklists that included novel items asking yes/no questions about whether physician-participants did “change a medication” or “recommend a health behavior change(s)”, and also asked what information from the FH or GS reports motivated the discussion.

Changes to health behaviors. Patient surveys administered 6 weeks and 6 months post disclosure included items adapted from multiple trials of genetic risk for Alzheimer's disease that asked, “Have you made any of the following health or wellness changes that were specifically motivated by the information you discussed with your doctor?” Response options were “diet,” “exercise,” “use of vitamins/herbal supplements”, “use of medications”, and “other”. An aggregated measure of “any change” was created to indicate whether patients endorsed a change to any of the five response options.

Psychological outcomes

General anxiety and depression. At each time point, including baseline, patients completed the Hospital Anxiety and Depression Scale, a commonly used 14-item instrument that addresses general anxiety and depression, and has been validated in general adult populations. Scores on subscales assessing anxiety and depression range from 0 to 21 (normal: 0–7; mild: 8–10; moderate: 11–14; severe: 15–21).

Test-related impact. As part of the 6-week and 6-month follow-up questionnaires, patients completed an adapted version of the Multi-dimensional Impact of Cancer Risk Assessment (MICRA). The scale assessed patients’ psychological responses to the information they received during MedSeq on three subscales as follows: distress, uncertainty, and positive impact. Patients rated how much “the information you discussed with your doctor as part of this study” made them experience feelings such as upset, happy, and guilty during the prior week. Response options of “not at all,” “a little,” “somewhat,” “a good deal”, and “a great deal” were scored 0–4, respectively, and scored into the subscales measuring distress (6 items, range 0–24, Cronbach’s α = 0.86), uncertainty (9 items, range 0–36, α = 0.77), and positive impact (4 reverse-scored items, range 0–16, α = 0.75). Higher scores on the distress and uncertainty subscales indicated stronger distress and uncertainty, whereas higher scores on the positive impact subscale indicated stronger negative feelings. Although the MICRA was originally developed and validated to assess responses to genetic susceptibility to hereditary breast and ovarian cancer, it has been adapted and undergone preliminary validation work that included asymptomatic adults to assess the impact of genetic risk disclosure for other contexts, including genetic susceptibility testing for Alzheimer disease and genomic sequencing. Of note, the MICRA has been adapted in multiple research consortia to examine the test-related impact of genomic sequencing.

Affective responses. Novel items administered in each follow-up survey assessed whether the information patients discussed with their doctor made them feel happy, empowered, relieved, worried, confused, or disappointed since completing their last survey. Response options included “not at all”, “slightly”, “moderately”, “very”, and “extremely”. These items were also administered at baseline and patients were asked to rate the likelihood (“no”, “probably no”, “probably yes”, and “yes”) that their results would make them feel these emotions.

Data analysis

Given the exploratory nature of this pilot trial, we did not set enrollment targets to power specific analyses and instead set targets for disclosure sessions with 100 primary-care and 100 cardiology patients. However, we tested the following a priori hypotheses: (a) patient-participants in the GS arm would be more likely than patient-participants in the control arm to report a change to at least one health behavior and (b) distress would be equivalent between patient-participants in the GS and control arms. Analyses included all patient-participants who had disclosure sessions where FH results and GS results, if applicable, were discussed. Analyses omitted four randomized patient-participants who did not have disclosure sessions, including two who died, one who withdrew due to concerns about potential genetic discrimination, and one who was lost to follow-up. Changes to smoking status were assessed but omitted from reporting, because only four smokers enrolled in the study. Unless otherwise noted, we dichotomized single-item measures of affective responses to compare responses of “slightly”, “moderately”, “very”, and “extremely” against “not at all”, given ordinal response options and highly skewed data. Analyses comparing randomization arms on physician-participant recommendations used logistic regression and controlled for cardiology or primary-care cohort. We used generalized linear models fit with generalized estimating equations in longitudinal analyses for all other outcomes, incorporating an independent working correlation structure with robust standard errors to account for repeated measures within a participant. For anxiety, depression, distress, and uncertainty, separate models for each outcome were fit with a log-link and normally distributed errors to compare scores by randomization status given skewed data. A value of 1 was added to these measures to shift the distribution away from zero. For models that analyzed positive impact, we used an identity link and normal distribution to compare scores to randomization status. For models that examined dichotomous outcomes (health behavior changes and affective responses), we used a logit link and binomial distribution. Primary models included terms for randomization status, time as a categorical variable, time-randomization interaction, and baseline score, where applicable. We also ran models that adjusted for whether prior genetic testing had identified a variant associated with a cardiology patient’s DCM or HCM diagnosis, but omitted this variable from all final models, because it was not associated with outcomes of interest (all p > 0.05). Cohort-specific analyses were conducted with models that also included terms for cohort, time–cohort interaction, randomization–cohort interaction, and time–cohort–randomization interaction. In the GS arm, we conducted exploratory analyses to examine the impact of high-risk genetic findings, defined as (A) the presence of an unexpected monogenic disease risk or (B) polygenic risk predictions for cardiometabolic traits in the 80th percentile or higher (i.e., higher risk predictions than 80% of the population). Monogenic findings associated with HCM or DCM for cardiology patients were omitted from these analyses given that these indication-based findings had all been disclosed previously, with only one exception. Analyses of discrimination for expected monogenic disease risks were conducted by including a term in regression models that indicated the presence or absence of monogenic disease risk. Analyses of the impact of disclosing polygenic risk predictions were conducted by including a
term in regression models that indicated the number of high-risk polygenic risk predictions (0–8) a patient was found to have.

Finally, exploratory analyses examined whether indirect relationships existed between randomization to GS and health behavior changes, where GS may have caused a change to a psychological outcome, which was itself associated with behavior changes. These analyses treated ordinal affective response variables as continuous variables given the size of the study and number of response options59. Psychological outcomes were considered for mediation if their scores at 6 weeks had bivariate associations at p < 0.05 with randomization status and bivariate associations at p < 0.05 with health behavior change at 6 months. We also tested whether physician recommendations any mediation effects of physician recommendations, given the importance of providers’ responses on patient outcomes. We conducted model-based causal mediation analyses using the *mediate* package in R, to estimate the direct and indirect effects of randomization to GS60. First, we created regression models to predict scores at 6 weeks of potential mediators (i.e., selected psychological outcomes and provider recommendations) based on randomization status. Second, we created probit regression models to predict the likelihood that patient-participants would report a health behavior change at 6 months based on randomization status, after controlling for scores of potential mediators at 6 weeks. Mediataion analyses with 1000 simulations used parameter estimates from these models to estimate indirect effects (i.e., the differences between randomization arms that could be attributed to the impact of GS on the mediator) and direct effects (i.e., the differences between randomization arms that were independent of the impact of GS on the mediator). Confidence intervals were estimated based on nonparametric bootstrapping.

As this was a pilot trial, we asserted statistical significance at α = 0.05 on all outcomes and used two-sided tests in all analyses. To test the hypothesis that patient-participants randomized to the GS arm would show equivalent levels of anxiety and depression as patient-participants randomized to the control arm, we asserted equivalence if confidence intervals for the mean differences on HADS subscales were <1.5 points, as defined as the minimal clinically important difference in other studies61. Per best practice recommendations, missing data were handled with multiple imputation62,63. We used the mice package for R and ran 100 iterations to create each of 20 imputed datasets using fully conditional specification64. We also ran statistical models on available data and highlight instances where available-case analyses did not support analyses of imputed data.

**Reporting summary**

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**DATA AVAILABILITY**

The datasets generated and/or analyzed during the current study are not publicly available to protect the privacy of participants, but are available from the corresponding author on reasonable request.

**CODE AVAILABILITY**

Analytic code for these analyses was written for R version 4.0.3, including the mice package version 3.8.0. This code is available from the corresponding author on reasonable request.

Received: 2 October 2019; Accepted: 30 July 2021; Published online: 24 August 2021

**REFERENCES**

1. McCarthy, J. J., McLeod, H. L. & Ginsburg, G. S. Genomic medicine: a decade of successes, challenges, and opportunities. *Sci. Transl. Med.*, 5, 189sr184–189sr184 (2013).

2. Manolio, T. A. Incorporating whole-genome sequencing into primary care: falling barriers and next steps. *Ann. Intern. Med.*, 167, 204–205 (2017).

3. Armstrong, K. Can genomics bend the cost curve? *JAMA*, 307, 1031–1032 (2012).

4. Yu, J.-H., Harrell, T. M., Jamal, S. M., Tabor, H. K. & Bamshad, M. J. Attitudes of genetics professionals toward the return of incidental results from exome and whole-genome sequencing. *Am. J. Hum. Genet.*, 95, 77–84 (2014).

5. Wolf, S. M., Annas, G. J. & Elias, S. Point-counterpoint. Patient autonomy and incidental findings in clinical genomics. *Science*, 340, 1049–1050 (2013).

6. Weiner, C. Anticipate and communicate: ethical management of incidental and secondary findings in the clinical, research, and direct-to-consumer contexts (December 2013 report of the Presidential Commission for the Study of Bioethical Issues). *Am. J. Epidemiol.*, 180, 562–564 (2014).

7. Glasgow, R. E., Ryan, L. R. & Mitchenall, D. D. Realizing the full potential of precision health: the need to include patient-reported health behavior, mental health, social determinants, and patient preferences data. *J. Clin. Transl. Sci.*, 2, 183–185 (2018).

8. McBride, C. M., Koehly, L. M., Sanderson, S. C. & Kaphingst, K. A. The behavioral response to personalized genetic information: will genetic risk profiles motivate individuals and families to choose more healthful behaviors? *Annu. Rev. Public Health*, 31, 89–103 (2010).

9. Marteau, T. M. et al. Effects of communicating DNA-based disease risk estimates on risk-reducing behaviours. *Cochrane Database Syst. Rev.*, 10, CD007275 (2010).

10. Blos, C. S., Schork, N. J. & Topol, E. J. Effect of direct-to-consumer genomics profiling to assess disease risk. *N. Engl. J. Med.*, 364, 524–534 (2011).

11. Blos, C. S., Winer, N. E., Darst, B. F., Schork, N. J. & Topol, E. J. Impact of direct-to-consumer genomic testing at long term follow-up. *J. Med. Genet.*, 50, 393–400 (2013).

12. Yanes, T., Willis, A. M., Meiser, B., Tucker, K. M. & Best, M. Psychosocial and behavioral outcomes of genomic testing in cancer: a systematic review. *Eur. J. Hum. Genet.*, 27, 28–35 (2019).

13. Sie, A. S. et al. Patient experiences with gene panels based on exome sequencing in clinical diagnostics: high acceptance and low distress. *Clin. Genet.*, 87, 319–326 (2015).

14. Christensen, K. D. et al. Disclosing pleiotropic effects during genetic risk assessment for Alzheimer disease. a randomized trial. *Ann. Intern. Med.*, 164, 155–163 (2016).

15. Wasson, K., Sanders, T. N., Hogan, N. S., Cherry, S. & Heldszouner, K. J. Primary care patients’ views and decisions about, experience of and reactions to direct-to-consumer genetic testing: a longitudinal study. *J. Community Genet.*, 4, 495–505 (2013).

16. Green, R. C. et al. Disclosure of APOE genotype for risk of Alzheimer’s disease. *N. Engl. J. Med.*, 361, 245–254 (2009).

17. Hartz, S. M. et al. Return of individual genetic results in a high-risk sample: enthusiasm and positive behavioral change. *Genet. Med.*, 17, 374–379 (2015).

18. Christensen, K. D. & Green, R. C. How could disclosing incidental information from whole-genome sequencing affect patient behavior? *Per Med.*, 10, 377–386 (2013).

19. Gray, S. W. et al. Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group. *Genet. Med.*, 16, 727–735 (2014).

20. Vassy, J. L. et al. The impact of whole genome sequencing on the primary care and outcomes of healthy adult patients: a pilot randomized trial. *Ann. Intern. Med.*, 167, 159–169 (2017).

21. Robinson, J. O. et al. Psychological outcomes related to exome and genome sequencing result disclosure: a meta-analysis of seven Clinical Sequencing Exploratory Research (CSER) Consortium studies. *Genet. Med.*, 21, 2781–2790 (2019).

22. Vassy, J. et al. The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine. *Trials*, 15, 85 (2014).

23. Greene, J., Hibbard, J. H., Alvarez, C. & Overton, V. Supporting patient behavior change: approaches used by primary care clinicians whose patients have an increase in activation levels. *Ann. Fam. Med.*, 14, 148–154 (2016).

24. Whitlock, E. P., Orleans, C. T., Pender, N. & Allan, J. Evaluating primary care behavioral counseling interventions: an evidence-based approach. *Am. J. Prev. Med.*, 22, 267–284 (2002).

25. Cirino, A. L. et al. A comparison of whole genome sequencing to multigene panel testing in hypertrophic cardiomyopathy patients. *Circ. Cardiovasc. Genet.*, 10, e001768 (2017).

26. Christensen, K. D. et al. Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. *Genet. Med.*, 20, 1544–1553 (2018).

27. Machini, K. et al. Analyzing and reanalyzing the genome: findings from the MedSeq Project. *Am. J. Hum. Genet.*, 105, 177–188 (2019).

28. Kullo, I. J. et al. Incorporating a genetic risk score into coronary heart disease risk estimates: effect on low-density lipoprotein cholesterol levels (the Mi-GENES Clinical Trial). *Circulation*, 133, 1181–1188 (2016).

29. McLaughlin, H. M. et al. A systematic approach to the reporting of medically relevant findings from whole genome sequencing. *BMC Med. Genet.*, 15, 134 (2014).

30. Green, R. C. et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genet. Med.*, 15, 565–574 (2013).
31. Kalia, S. S. et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update [ACMG SF v2.0]: a policy statement of the American College of Medical Genetics and Genomics. Genet. Med. 19, 249–255 (2017).
32. Roberts, J. S. et al. Patient understanding of, satisfaction with, and perceived utility of whole-genome sequencing: findings from the MedSeq Project. Genet. Med. 20, 1069–1076 (2018).
33. Arora, N. S. et al. Communication challenges for nongeneticists physicians relaying clinical genomic results. Per Med. 14, 423–431 (2016).
34. Vassy, J. L. et al. How primary care providers talk to patients about genome sequencing results: risk, rationale, and recommendation. J. Gen. Intern. Med. 33, 877–885 (2018).
35. Leventhal, H., Leventhal, E. A. & Contrada, R. J. Self-regulation, health, and behavior: a perceptual-cognitive approach. Psychol. Health 13, 717–733 (1998).
36. Witte, K. Putting the fear back into fear appeals: the extended parallel process model. Commun. Monogr. 59, 329–349 (1992).
37. Lazarus, R. S. & Folkman, S. Stress, Appraisal, and Coping (Springer, 1984).
38. Fredrickson, B. L. & Joiner, T. Reflections on positive emotions and upward spirals. Perspect. Psychol. Sci. 13, 194–199 (2018).
39. Van Cappellen, P., Rice, E. L., Catalino, L. I. & Fredrickson, B. L. Positive affective processes underlie positive health behaviour change. Psychol. Health 33, 77–97 (2018).
40. McBride, C. M. et al. Future health applications of genomics: priorities for communication, behavioral, and social sciences research. Am. J. Prev. Med. 38, 556–565 (2010).
41. Lewis, K. L. et al. Participant use and communication of findings from exome sequencing: a mixed-methods study. Genet. Med. 18, 577–583 (2016).
42. Sanderson, S. C. et al. How do students react to analyzing their own genomes in a whole-genome sequencing course? Outcomes of a longitudinal cohort study. Genet. Med. 17, 866–874 (2015).
43. Zigmond, A. S. & Snaith, R. P. The Hospital Anxiety and Depression Scale. Acta Psychiatr. Scand. 67, 361–370 (1983).
44. Shiloh, S. Illness representations, self-regulation, and genetic counseling: a theoretical review. J. Genet. Couns. 15, 325–337 (2006).
45. Butterfield, R. M. et al. Returning negative results to individuals in a genomic screening program: lessons learned. Genet. Med. 21, 401–416 (2019).
46. Robinson, J. O. et al. Participants and study decliners’ perspectives about the risks of participating in a clinical trial of whole genome sequencing. J. Empir. Res. Hum. Ethic. 11, 21–30 (2016).
47. Lane, W. J. et al. Comprehensive red blood cell and platelet antigen prediction from whole-genome sequencing: proof of principle. Transfusion 56, 743–754 (2016).
48. Kong, S. W. et al. Summarizing polygenic risks for complex diseases in a clinical whole-genome report. Genet. Med. 17, 536–544 (2015).
49. Vassy, J. L. et al. A one-page summary report of genome sequencing for the healthy adult. Public Health Genomics 18, 123–129 (2015).
50. Facio, F. M. et al. Validation of my family health portrait for six common heritable conditions. Genet. Med. 12, 370–375 (2010).
51. Chao, S. et al. Health behavior changes after genetic risk assessment for Alzheimer disease: the REVEAL Study. Alzheimer Dis. Assoc. Disord. 22, 94–97 (2008).
52. Vernarelli, J. A. et al. in 2009 Annual Clinical Genetics Meeting (American College of Medical Genetics, Tampa, Florida, 2009).
53. Christensen, K. D. et al. Disclosing genetic risk for Alzheimer’s dementia to individuals with mild cognitive impairment. Alzheimers Dement. 6, e12002 (2020).
54. Bjelland, I., Dahl, A. A., Haug, T. T. & Neckelmann, D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J. Psychosom. Res. 52, 69–77 (2002).
55. Celli, D. et al. A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol. 21, 564–572 (2002).
56. Chung, W. W. et al. A new scale measuring psychologic impact of genetic susceptibility testing for Alzheimer disease. Alzheimer Dis. Assoc. Discord. 23, 50–56 (2009).
57. Li, M. et al. The Feelings About genomic Testing Results (FACTOR) questionnaire: development and preliminary validation. J. Genet. Couns. 28, 477–490 (2019).
58. Wiesner, G. L. et al. Returning results in the genomic era: initial experiences of the eMERGE Network. J. Pers. Med. 10, 30 (2020).
59. Harris, R. J. A Primer of Multivariate Statistics (Psychology, 2001).
60. Imai, K., Keele, L. & Tingley, D. A general approach to causal mediation analysis. Psychol. Methods 15, 309–334 (2010).
61. Puhan, M. A., Frey, M., Buchi, S. & Schunemann, H. J. The minimal important difference of the hospital anxiety and depression scale in patients with chronic obstructive pulmonary disease. Health Qual. Life Outcomes 6, 46 (2008).
62. Rehal, S., Morris, T. P., Fielding, K., Carpenter, J. R. & Phillips, P. P. Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals. BMJ Open 6, e012594 (2016).
63. Sterne, J. A. C. et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338, b2393 (2009).
64. van Buuren, S. & Groothuis-Oudshoorn, K. MICE: multivariate imputation by chained equations in R. J. Stat. Softw. 45, 1–67 (2011).

ACKNOWLEDGEMENTS

Investigators on the MedSeq Project are listed in Supplementary Note 1. This study was supported by NIH grants U01-HG006500, K01-HG009173, and R01-HD090019. This work was also supported by Harvard Catalyst [The Harvard Clinical and Translational Science Center (National Center for Research Resources and National Center for Advancing Translational Sciences, NIH grant UL1-TR001102), and financial contributions from Harvard University and its affiliated academic healthcare centers. We thank SAM Solutions, Inc. (Rockville, MD, USA), for their help in customizing the workflow of the “My Family Health Portrait” web tool for this study. We also thank Lauren Galbraith for her assistance preparing the manuscript.

AUTHOR CONTRIBUTIONS

K.D.C., J.O.R., J.S.R., P.M.D., R.C.G., and A.L.M. were responsible for conception or design of the work. E.F.S., J.O.R., K.B.L., R.C.G., and A.L.M. were responsible for the data collection. K.D.C., J.O.R., and P.M.D. were responsible for the data analysis and interpretation. K.D.C. drafted the article. All authors provided critical revisions to the manuscript and read, approved, and agree to be accountable for all aspects of the work of the final manuscript.

COMPETING INTERESTS

R.C.G. has received compensation for advising the following companies: AIA, Genomic Life, Grail, Humanity, Kneed Media, Plumcare, UnitedHealth, Verily, Vibrant Health, and is co-founder of Genome Medical, Inc., a technology and services company providing genetics expertise to patients, providers, employers, and care systems. The other authors declare no competing interests.

CONSENT TO PUBLISH

Not applicable.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41525-021-00236-2.

Correspondence and requests for materials should be addressed to K.D.C.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021